Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.3335
−$0.0265 · -0.61%
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Regular session
$4.3335
−$0.0265 · -0.61%
Regular session · ET · Market data may be delayed.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Day range
Current $4.3335
52-week range
Current $4.3335
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
42
Fair Value
Sentiment
36
Bearish
Risk
64
High Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Day range
Current $4.3335
52-week range
Current $4.3335
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 84.28M USD | 89.15M USD | 30K USD | 1.32M USD | 5.51M USD |
| Cost of goods sold | 20.42M USD | 20.56M USD | — | 17.12M USD | 213K USD |
| Gross profit | 63.86M USD | 68.59M USD | 30K USD | −15.8M USD | 5.29M USD |
| Research and development | 13.18M USD | 19.58M USD | 20.27M USD | 18.38M USD | 20.27M USD |
| Selling, general, and administrative | 230.12M USD | — | 47.28M USD | 18.66M USD | 4.69M USD |
| Operating expenses | 243.3M USD | 71.68M USD | 67.55M USD | 19.71M USD | 24.75M USD |
| Interest income | 10.67M USD | — | — | — | 800K USD |
| Interest expense | 2.6M USD | — | — | — | 106K USD |
| Depreciation and amortization | 1.37M USD | 79K USD | 73K USD | 319K USD | 213K USD |
| Operating income | −179.45M USD | −3.08M USD | −67.52M USD | −35.52M USD | −19.45M USD |
| Net income | −171.3M USD | 8M USD | −54.37M USD | −34.68M USD | −20.24M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.5M0.00%2.3T USD0.03%$379.52-0.40%
State Street SPDR S&P Biotech ETFXBI9.79M0.09%10.08B USD0.35%$147.01-2.14%
iShares Russell 2000 ETFIWM7.15M0.01%78.56B USD0.19%$274.8-1.04%
Vanguard Extended Market ETFVXF4.58M0.00%95.4B USD0.05%$231.42-0.89%
iShares Russell 2000 Growth ETFIWO2.54M0.02%14.25B USD0.24%$350.63-1.34%
Vanguard Russell 2000 ETFVTWO2.13M0.01%18B USD0.06%$110.99-1.09%
iShares Biotechnology ETFIBB2.06M0.02%10.4B USD0.44%$197.82-2.71%
Schwab U.S. Small-Cap ETFSCHA1.43M0.01%21.7B USD0.03%$32.305-0.94%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
